Payment overview · 2025
General Payments
$256.88
13 reported records · 7 companies
Healthcare provider profile · identity verified
Sushan Joshi
Allopathic & Osteopathic Physicians|Internal Medicine · TORRANCE, CA · NPI 1982851143
Verified facts
What the public records show
CMS Open Payments records show Sushan Joshi received $256.88 in general payments during 2025 across 13 reported records.
PFIZER INC. accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $81.55 | 31.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $55.12 | 21.5% | 3 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.73 | 15.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.36 | 11.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.38 | 7.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.16 | 6.7% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $15.58 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $256.88 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $81.55 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $81.55 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $58.37 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $55.12 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $55.12 | 3 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $39.73 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.36 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.36 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 327 | 165 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 89 |
| Amlodipine Besylate | Amlodipine Besylate | 174 | 87 |
| Irbesartan | Irbesartan | 172 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 163 | 66 |
| Gabapentin | Gabapentin | 141 | 63 |
| Lisinopril | Lisinopril | 127 | 65 |
| Omeprazole | Omeprazole | 113 | 61 |
| Alendronate Sodium | Alendronate Sodium | 104 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 36 |
| Eliquis | Apixaban | 89 | 29 |
| Furosemide | Furosemide | 87 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 37 |
| Potassium Chloride | Potassium Chloride | 86 | 42 |
| Losartan Potassium | Losartan Potassium | 82 | 37 |
| Simvastatin | Simvastatin | 81 | 35 |
| Carvedilol | Carvedilol | 77 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 26 |
| Metformin Hcl | Metformin Hcl | 74 | 40 |
| Spironolactone | Spironolactone | 72 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 36 |
| Warfarin Sodium | Warfarin Sodium | 63 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 54 | 14 |
| Meloxicam | Meloxicam | 53 | 30 |
| Famotidine | Famotidine | 51 | 24 |
| Montelukast Sodium | Montelukast Sodium | 51 | 17 |
| Ezetimibe | Ezetimibe | 50 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 25 |
| Valsartan | Valsartan | 48 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 24 |
| Ventolin Hfa | Albuterol Sulfate | 43 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 22 |
| Allopurinol | Allopurinol | 41 | 17 |
| Trazodone Hcl | Trazodone Hcl | 38 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 17 |
| Pregabalin | Pregabalin | 36 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 33 | 11 |
| Ozempic | Semaglutide | 32 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 31 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | 12 |
| Metformin Hcl Er | Metformin Hcl | 29 | 15 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Prednisone | Prednisone | 28 | 14 |
| Jardiance | Empagliflozin | 27 | 13 |
| Atenolol | Atenolol | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | 16 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Glipizide | Glipizide | 26 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 26 | 14 |
| Mirtazapine | Mirtazapine | 26 | 12 |
| Sertraline Hcl | Sertraline Hcl | 26 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 25 | 11 |
| Baclofen | Baclofen | 24 | suppressed |
| Celecoxib | Celecoxib | 24 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | 11 |
| Tramadol Hcl | Tramadol Hcl | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Azithromycin | Azithromycin | 22 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | 11 |
| Digoxin | Digoxin | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Chlorthalidone | Chlorthalidone | 19 | 11 |
| Nystatin | Nystatin | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Methocarbamol | Methocarbamol | 16 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Cilostazol | Cilostazol | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.88 · 13 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, COMIRNATY, CREON, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, OTEZLA, PREVNAR 20, PYRUKYND, REPATHA, SHINGRIX | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error